Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus

The Middle East respiratory syndrome coronavirus (MERS-CoV) is a highly pathogenic and zoonotic virus with a fatality rate in humans of over 35%. Although several vaccine candidates have been developed, there is still no clinically available vaccine for MERS-CoV. In this study, we developed two type...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Seo-Yeon, Kang, Kyung Won, Lee, Eun-Young, Seo, Dong-Won, Kim, Hong-Lim, Kim, Hak, Kwon, TaeWoo, Park, Hye-Lim, Kim, Hun, Lee, Sang-Myeong, Nam, Jae-Hwan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115429/
https://www.ncbi.nlm.nih.gov/pubmed/29739720
http://dx.doi.org/10.1016/j.vaccine.2018.04.082

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115429/
https://www.ncbi.nlm.nih.gov/pubmed/29739720
http://dx.doi.org/10.1016/j.vaccine.2018.04.082

Ejemplares similares